Shares of Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) traded down 2.5% during trading on Thursday . The stock traded as low as $0.86 and last traded at $0.86. 1,250 shares changed hands during trading, an increase of 97% from the average session volume of 635 shares. The stock had previously closed at $0.88.
Defence Therapeutics Stock Performance
The company’s fifty day moving average is $1.17 and its 200 day moving average is $1.55.
About Defence Therapeutics
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
Recommended Stories
- Five stocks we like better than Defence Therapeutics
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 4/29 – 5/3
- Overbought Stocks Explained: Should You Trade Them?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What Does a Stock Split Mean?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
